Research programme: spinal cord injury therapies - ProthericsAlternative Names: Nanotechnology therapies
Latest Information Update: 23 Nov 2009
At a glance
- Originator Protherics
- Mechanism of Action Nerve growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 02 Dec 2003 Preclinical trials in Spinal cord injuries in United Kingdom (unspecified route)